|
US3655679A
(en)
|
1969-06-25 |
1972-04-11 |
Merck & Co Inc |
Certain aryl pyridine carboxylic acid derivatives
|
|
US3703582A
(en)
|
1970-04-20 |
1972-11-21 |
Merck & Co Inc |
Aryl pyridine carboxylic acids in the treatment of inflammation
|
|
US3894920A
(en)
|
1971-12-21 |
1975-07-15 |
Sagami Chem Res |
Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives
|
|
US4016287A
(en)
|
1972-07-17 |
1977-04-05 |
Boehringer Ingelheim Gmbh |
Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof
|
|
CA1261335A
(en)
|
1984-08-29 |
1989-09-26 |
Hoffmann-La Roche Limited/Hoffmann-La Roche Limitee |
Ethylenediamine monoamide derivatives
|
|
CN1023479C
(zh)
|
1985-09-27 |
1994-01-12 |
弗·哈夫曼-拉罗切有限公司 |
乙二胺的单酰胺衍生物的制备方法
|
|
TW219933B
(https=)
|
1990-02-26 |
1994-02-01 |
Lilly Co Eli |
|
|
US5405613A
(en)
|
1991-12-11 |
1995-04-11 |
Creative Nutrition Canada Corp. |
Vitamin/mineral composition
|
|
TW352384B
(en)
|
1992-03-24 |
1999-02-11 |
Hoechst Ag |
Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
|
|
DE4219158A1
(de)
|
1992-06-11 |
1993-12-16 |
Thomae Gmbh Dr K |
Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
|
|
DK0650961T3
(da)
|
1993-11-02 |
1997-09-15 |
Hoechst Ag |
Substituerede heterocykliske carboxylsyreamider, deres fremstilling og deres anvendelse som lægemidler.
|
|
ATE149485T1
(de)
|
1993-11-02 |
1997-03-15 |
Hoechst Ag |
Substituierte heterocyclische carbonsäureamidester, ihre herstellung und ihre verwendung als arzneimittel
|
|
NZ270267A
(en)
|
1993-12-30 |
1997-03-24 |
Hoechst Ag |
3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions
|
|
DE4410423A1
(de)
|
1994-03-25 |
1995-09-28 |
Hoechst Ag |
Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
|
DE4410480A1
(de)
|
1994-03-25 |
1995-09-28 |
Hoechst Ag |
Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
|
US5789426A
(en)
|
1995-01-20 |
1998-08-04 |
Cornell Research Foundation, Inc. |
Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation
|
|
IL135495A
(en)
|
1995-09-28 |
2002-12-01 |
Hoechst Ag |
Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
|
|
JPH09221476A
(ja)
|
1995-12-15 |
1997-08-26 |
Otsuka Pharmaceut Co Ltd |
医薬組成物
|
|
CA2253282A1
(en)
|
1996-04-30 |
1997-11-06 |
Hoechst Aktiengesellschaft |
3-alkoxypyridine-2-carboxylic acid amide esters, their preparation and their use as drugs
|
|
DE19620041A1
(de)
|
1996-05-17 |
1998-01-29 |
Merck Patent Gmbh |
Adhäsionsrezeptor-Antagonisten
|
|
DE19650215A1
(de)
|
1996-12-04 |
1998-06-10 |
Hoechst Ag |
3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
|
|
EP1024134A4
(en)
|
1997-10-09 |
2003-05-14 |
Ono Pharmaceutical Co |
DERIVATIVES OF AMINOBUTANIC ACID
|
|
DE19746287A1
(de)
|
1997-10-20 |
1999-04-22 |
Hoechst Marion Roussel De Gmbh |
Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
|
|
EP1080075B1
(en)
|
1998-03-23 |
2004-08-11 |
Aventis Pharmaceuticals Inc. |
Piperididinyl and n-amidinopiperidinyl derivatives
|
|
US6159379A
(en)
|
1999-05-04 |
2000-12-12 |
Baker Hughes Incorporated |
Organic ammonium salts for the removal of water soluble organics in produced water
|
|
JP2001048786A
(ja)
|
1999-08-05 |
2001-02-20 |
Yamanouchi Pharmaceut Co Ltd |
三環式ヘテロアリール誘導体
|
|
BR0108846A
(pt)
*
|
2000-03-22 |
2003-05-06 |
Upjohn Co |
Formulação de oxazolidinona em comprimido
|
|
US6589758B1
(en)
|
2000-05-19 |
2003-07-08 |
Amgen Inc. |
Crystal of a kinase-ligand complex and methods of use
|
|
US6849718B2
(en)
|
2001-03-20 |
2005-02-01 |
Dana Farber Cancer Institute, Inc. |
Muteins of hypoxia inducible factor alpha and methods of use thereof
|
|
US6855510B2
(en)
|
2001-03-20 |
2005-02-15 |
Dana Farber Cancer Institute, Inc. |
Pharmaceuticals and methods for treating hypoxia and screening methods therefor
|
|
JP4590157B2
(ja)
|
2001-03-21 |
2010-12-01 |
アイシス イノヴェイション リミテッド |
アッセイ、方法および手段
|
|
SE0101327D0
(sv)
|
2001-04-12 |
2001-04-12 |
Astrazeneca Ab |
New crystalline forms
|
|
US6566088B1
(en)
|
2001-10-04 |
2003-05-20 |
Board Of Regents, The University Of Texas System |
Prolyl-4-hydroxylases
|
|
GB0124941D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
DK2298301T3
(en)
|
2001-12-06 |
2018-10-01 |
Fibrogen Inc |
MEDICINALS FOR TREATMENT OF ANEMIA ASSOCIATED WITH Kidney Disease
|
|
EP2258363A1
(en)
|
2002-05-17 |
2010-12-08 |
Celgene Corporation |
Compositions for treatment of cancers
|
|
RU2005108667A
(ru)
|
2002-08-29 |
2005-08-27 |
Мерк энд Ко., Инк. (US) |
Производные n-биарилметиламиноциклоалканкарбоксамида
|
|
WO2004035812A2
(en)
|
2002-10-16 |
2004-04-29 |
Isis Innovation Limited |
Asparaginyl hydroxylases and modulators thereof
|
|
AU2003298611A1
(en)
|
2002-11-21 |
2004-06-18 |
Eli Lilly And Company |
Mixed lineage kinase modulators
|
|
US8124582B2
(en)
|
2002-12-06 |
2012-02-28 |
Fibrogen, Inc. |
Treatment of diabetes
|
|
US7618940B2
(en)
|
2002-12-06 |
2009-11-17 |
Fibrogen, Inc. |
Fat regulation
|
|
US7183287B2
(en)
|
2003-04-03 |
2007-02-27 |
Pharmacia Corporation |
Substituted pyrimidinones
|
|
WO2004108681A1
(en)
|
2003-06-06 |
2004-12-16 |
Fibrogen, Inc. |
Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
|
|
US8614204B2
(en)
|
2003-06-06 |
2013-12-24 |
Fibrogen, Inc. |
Enhanced erythropoiesis and iron metabolism
|
|
US20060251638A1
(en)
|
2003-06-06 |
2006-11-09 |
Volkmar Guenzler-Pukall |
Cytoprotection through the use of hif hydroxylase inhibitors
|
|
GB0314129D0
(en)
|
2003-06-18 |
2003-07-23 |
Astrazeneca Ab |
Therapeutic agents
|
|
JPWO2005108370A1
(ja)
|
2004-04-16 |
2008-03-21 |
味の素株式会社 |
ベンゼン化合物
|
|
ZA200610164B
(en)
|
2004-05-28 |
2008-02-27 |
Fibrogen Inc |
HIF prolyl hydroxylase activity assay
|
|
TW200609218A
(en)
|
2004-05-31 |
2006-03-16 |
Tanabe Seiyaku Co |
Bicyclic compounds
|
|
WO2006019831A1
(en)
|
2004-07-14 |
2006-02-23 |
Ptc Therapeutics, Inc. |
Methods for treating hepatitis c
|
|
TW200616969A
(en)
|
2004-09-17 |
2006-06-01 |
Tanabe Seiyaku Co |
Imidazole compound
|
|
CN101111245A
(zh)
*
|
2005-01-27 |
2008-01-23 |
阿雷姆贝克有限公司 |
左乙拉西坦延长释放制剂
|
|
US20080213404A1
(en)
|
2005-02-04 |
2008-09-04 |
Johnson Randall S |
Hif Modulating Compounds and Methods of Use Thereof
|
|
DE102005019712A1
(de)
|
2005-04-28 |
2006-11-09 |
Bayer Healthcare Ag |
Dipyridyl-dihydropyrazolone und ihre Verwendung
|
|
AU2006254897A1
(en)
|
2005-06-06 |
2006-12-14 |
Fibrogen, Inc. |
Improved treatment for anemia using a HIF-alpha stabilising agent
|
|
MX2007016160A
(es)
|
2005-06-15 |
2008-03-07 |
Fibrogen Inc |
Uso de moduladoers de hif-1 alfa para el tratamiento contra el cancer.
|
|
US20070154482A1
(en)
|
2005-09-12 |
2007-07-05 |
Beth Israel Deaconess Medical Center |
Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
|
|
WO2007038571A2
(en)
|
2005-09-26 |
2007-04-05 |
Smithkline Beecham Corporation |
Prolyl hydroxylase antagonists
|
|
WO2007047194A2
(en)
|
2005-10-11 |
2007-04-26 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating mitf-related disorders
|
|
EP1960363B1
(en)
|
2005-12-09 |
2014-01-22 |
Amgen, Inc. |
Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions and uses thereof
|
|
US20090023666A1
(en)
|
2006-01-09 |
2009-01-22 |
BTG plc |
Modulators of Hypoxia Inducible Factor-1 and Related Uses
|
|
WO2007082899A1
(en)
|
2006-01-17 |
2007-07-26 |
Vib Vzw |
Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
|
|
WO2007084667A2
(en)
|
2006-01-19 |
2007-07-26 |
Osi Pharmaceutical, Inc. |
Fused heterobicyclic kinase inhibitors
|
|
JP4801451B2
(ja)
|
2006-01-19 |
2011-10-26 |
株式会社日立ハイテクノロジーズ |
走査電子顕微鏡等に用いる電子銃の制御装置及び制御方法
|
|
ITMI20060179A1
(it)
|
2006-02-02 |
2007-08-03 |
Abiogen Pharma Spa |
Procedimento per la risoluzione di miscele racemiche e complesso diastereoisomerico di un agente risolvente e di unantiomero di interesse
|
|
US7625927B2
(en)
|
2006-02-27 |
2009-12-01 |
Alcon Research, Ltd. |
Method of treating glaucoma
|
|
US7588924B2
(en)
|
2006-03-07 |
2009-09-15 |
Procter & Gamble Company |
Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
|
|
AR059733A1
(es)
|
2006-03-07 |
2008-04-23 |
Smithkline Beecham Corp |
Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion
|
|
ES2288117B1
(es)
|
2006-05-08 |
2008-12-01 |
Combino Pharm, S.L. |
Composicion farmaceutica solida de gabapentina.
|
|
US20090176825A1
(en)
|
2006-05-16 |
2009-07-09 |
Fitch Duke M |
Prolyl hydroxylase inhibitors
|
|
JO2934B1
(en)
|
2006-06-23 |
2015-09-15 |
سميث كلاين بيتشام كوربوريشن |
Prolyl hydroxylase inhibitors
|
|
PL3357911T3
(pl)
|
2006-06-26 |
2022-09-05 |
Akebia Therapeutics Inc. |
Inhibitory prolilohydroksylazy i sposoby ich użycia
|
|
TW200845991A
(en)
|
2007-01-12 |
2008-12-01 |
Smithkline Beecham Corp |
N-substituted glycine derivatives: hydroxylase inhibitors
|
|
TW200845994A
(en)
|
2007-01-12 |
2008-12-01 |
Smithkline Beecham Corp |
N-substituted glycine derivatives: prolyl hydroxylase inhibitors
|
|
JP2008201711A
(ja)
*
|
2007-02-20 |
2008-09-04 |
Ss Pharmaceut Co Ltd |
システイン臭が低減された固形製剤
|
|
ES2446418T3
(es)
|
2007-04-18 |
2014-03-07 |
Amgen, Inc |
Derivados de indanona que inhiben la prolil hidroxilasa
|
|
JP2010524935A
(ja)
|
2007-04-18 |
2010-07-22 |
メルク・シャープ・エンド・ドーム・コーポレイション |
新規１，８−ナフチリジン化合物
|
|
US8030346B2
(en)
|
2007-05-04 |
2011-10-04 |
Amgen Inc. |
Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity
|
|
US8309544B2
(en)
|
2007-05-16 |
2012-11-13 |
Merck Sharp & Dohme Corp. |
Spiroindalones
|
|
CA2687306A1
(en)
|
2007-05-18 |
2008-11-27 |
Bayer Schering Pharma Aktiengesellschaft |
Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
|
|
EP2186528B1
(en)
|
2007-08-06 |
2014-03-19 |
Senju Pharmaceutical Co., Ltd. |
Pharmaceutical containing hif-1 alpha and hif-2 alpha expression inhibitor
|
|
TW200908984A
(en)
|
2007-08-07 |
2009-03-01 |
Piramal Life Sciences Ltd |
Pyridyl derivatives, their preparation and use
|
|
KR20100045480A
(ko)
|
2007-08-10 |
2010-05-03 |
크리스탈지노믹스(주) |
피리딘 유도체 및 이들의 사용방법
|
|
WO2009035534A2
(en)
|
2007-09-07 |
2009-03-19 |
The Cleveland Clinic Foundation |
Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif)
|
|
WO2009039321A1
(en)
|
2007-09-19 |
2009-03-26 |
Smithkline Beecham Corporation |
Prolyl hydroxylase inhibitors
|
|
WO2009039323A1
(en)
|
2007-09-19 |
2009-03-26 |
Smithkline Beecham Corporation |
Prolyl hydroxylase inhibitors
|
|
WO2009043093A1
(en)
|
2007-10-04 |
2009-04-09 |
Newsouth Innovations Pty Limited |
Hif inhibition
|
|
WO2009049112A1
(en)
|
2007-10-10 |
2009-04-16 |
Smithkline Beecham Corporation |
Prolyl hydroxylase inhibitors
|
|
WO2009067790A1
(en)
|
2007-11-26 |
2009-06-04 |
Uti Limited Partnership |
STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION
|
|
JP2011505367A
(ja)
|
2007-11-30 |
2011-02-24 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー |
プロリルヒドロキシラーゼ阻害剤
|
|
EA201000915A1
(ru)
|
2007-11-30 |
2011-02-28 |
ГЛЭКСОСМИТКЛАЙН ЭлЭлСи |
Ингибиторы пролилгидроксилазы
|
|
WO2009073669A1
(en)
|
2007-12-03 |
2009-06-11 |
Fibrogen, Inc. |
Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
|
|
EP2240178A4
(en)
|
2007-12-19 |
2011-10-26 |
Glaxosmithkline Llc |
PROLYLHYDROXYLASEHEMMER
|
|
WO2009086592A1
(en)
|
2008-01-04 |
2009-07-16 |
Garvan Institute Of Medical Research |
Method of increasing metabolism
|
|
EP2252619B1
(en)
|
2008-01-11 |
2013-10-09 |
Fibrogen, Inc. |
Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
|
|
CN102015651B
(zh)
|
2008-03-03 |
2014-12-31 |
Irm责任有限公司 |
作为tlr活性调节剂的化合物和组合物
|
|
EP2307372B1
(en)
|
2008-07-23 |
2012-04-25 |
F. Hoffmann-La Roche AG |
Heterocyclic antiviral compounds
|
|
KR20110063537A
(ko)
|
2008-09-15 |
2011-06-10 |
카시나 라일라 이노바 파마슈티칼스 프라이빗 리미티드 |
전이성 악성 흑색종 및 기타 암에 대한 항암 약물 및 이와 관련한 용도
|
|
JP5649584B2
(ja)
|
2008-11-14 |
2015-01-07 |
フィブロジェン インコーポレイテッド |
Ｈｉｆヒドロキシラーゼ阻害剤としてのチオクロメン誘導体
|
|
AU2010231615B2
(en)
|
2009-03-31 |
2014-05-15 |
Kissei Pharmaceutical Co., Ltd. |
Indolizine derivative and use thereof for medical purposes
|
|
RS54010B1
(sr)
|
2009-11-06 |
2015-10-30 |
Aerpio Therapeutics Inc. |
Inhibitori prolil hidroksilaze
|
|
AR079343A1
(es)
|
2009-12-21 |
2012-01-18 |
Lilly Co Eli |
Compuesto de acido 2-amino-4-(4h-1,2,4-triazol-3-ilsulfanil)biciclo[3.1.0]hexano-2,6-dicarboxilico, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar un trastorno psiquiatrico
|
|
US20140171465A1
(en)
*
|
2011-01-13 |
2014-06-19 |
Fibrogen, Inc. |
Methods For Increasing Reticulocyte Hemoglobin Content
|
|
WO2012170439A1
(en)
|
2011-06-06 |
2012-12-13 |
The Ohio State University |
Methods for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
|
|
NO2686520T3
(https=)
|
2011-06-06 |
2018-03-17 |
|
|
|
US20130022974A1
(en)
|
2011-06-17 |
2013-01-24 |
The Regents Of The University Of Michigan |
Dna methylation profiles in cancer
|
|
CN104024227B8
(zh)
|
2011-07-22 |
2025-07-29 |
北京贝美拓新药研发有限公司 |
抑制脯氨酸羟化酶活性的化合物的晶型及其应用
|
|
WO2013070908A1
(en)
|
2011-11-09 |
2013-05-16 |
Fibrogen, Inc. |
Therapeutic method
|
|
AU2013347264B2
(en)
|
2012-11-19 |
2016-10-27 |
Afyx Therapeutics A/S |
Dispersible tablet
|
|
KR20160061911A
(ko)
|
2013-04-08 |
2016-06-01 |
데니스 엠. 브라운 |
최적하 투여된 화학 화합물의 치료 효과
|
|
HRP20200615T1
(hr)
*
|
2013-06-06 |
2020-07-10 |
Fibrogen, Inc. |
Farmaceutske formulacije inhibitora hif hidroksilaze
|
|
JP2016521747A
(ja)
|
2013-06-13 |
2016-07-25 |
アケビア セラピューティクス インコーポレイテッドＡｋｅｂｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． |
貧血治療のための組成物及び方法
|
|
JP2016529257A
(ja)
|
2013-08-16 |
2016-09-23 |
オハイオ ステート イノベーション ファウンデーション |
Ｄｎａメチル化を調節する組成物及び方法
|
|
MY180626A
(en)
|
2013-11-15 |
2020-12-03 |
Akebia Therapeutics Inc |
Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
|
|
MX2016009331A
(es)
|
2014-01-23 |
2016-10-26 |
Akebia Therapeutics Inc |
Composiciones y metodos para tratar enfermedades oculares.
|
|
US10617716B2
(en)
|
2014-12-16 |
2020-04-14 |
Urgo Us, Inc. |
Hypochlorous acid formulations and methods for treating skin conditions
|
|
US10150734B2
(en)
|
2015-01-23 |
2018-12-11 |
Akebia Therapeutics, Inc. |
Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
|
|
US20180065933A1
(en)
|
2015-03-20 |
2018-03-08 |
Akebia Therapeutics, Inc. |
Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors
|
|
US11324734B2
(en)
|
2015-04-01 |
2022-05-10 |
Akebia Therapeutics, Inc. |
Compositions and methods for treating anemia
|